Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage

References

• Siegel, D. and Lopez, J. (1997). Trends in antihypertensive drug use in the United States. Do the JNCV recommendations affect prescribing? JAMA, 278, 1745–1748.
   PubMed Web of Science ®Google Scholar
• Cornoi-Huntley, J., LaCroix, A. Z. and Havlik, R. J. (1989). Race and sex differentials in the impact of hypertension in the United States. Arch. Intern. Med., 149, 780–788.
   PubMed Web of Science ®Google Scholar
• Flack, J. M., Neaton, J., Daniels, B. and Esunge, P. (1993). Ethnicity and renal disease: lessons from multiple risk factor intervention trial and treatment of mild hypertension study. Am. J. Kidney Dis., 21(4) (Suppl I), 31–40.
   PubMed Web of Science ®Google Scholar
• Roccella, E. J. and Lenfant, C. (1989). Regional and racial differences among stroke victims in the United States. UM. Cardiol., 12, IV-18-IV-22.
   Google Scholar
• Qualheim, R. E., Rostand, S. G., Kirk, K. A., Rutsky, E. A. and Luke, R. G. (1991). Changing patterns of end-stage renal disease due to hypertension. Am. J. Kidney Dis., 18, 336–343.
   PubMed Web of Science ®Google Scholar
• Flack, J. M., Ensrud, K. E., Mascioli, S. et al. (1991). Racial and ethnic modifiers of the salt-blood pressure response. Hypertension, 17 (Suppl I), I-115–I-121.
   Google Scholar
• Faulkner, B. and Kushner, H. (1990). Effect of chronic sodium loading on cardiovascular responses in young blacks and whites. Hypertension, 15, 36–43.
   PubMed Web of Science ®Google Scholar
• Suzuki, H., Ferrario, C. M., Speth, R. C. et al. (1983). Alterations in plasma and cerebrospinal fluid norepinephrine and angiotensin II during the development of renal hypertension in conscious dogs. Hypertension, 5 (Suppl I), I-139–I-148.
   Google Scholar
• Kohara, K., Brosnihan, K. B. and Ferrario, C. M. (1993). Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides, 14, 883–891.
   PubMed Web of Science ®Google Scholar
• Allan, D. R., McKnight, J. A., Kifor, I., Coletti, C. M. and Hollenberg, N. K. (1994). Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension, 24(4), 516–522.
   PubMed Web of Science ®Google Scholar
• Weishaar, R. E., Panck, R. L., Major, T. C., Simmerman, J., Rapundalo, S. T. and Taylor, D. G. Jr. (1991). Evidence for a functional tissue renin-angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure. J. Pharmacol. Expl. Ther, 256(2), 568–574.
   PubMed Web of Science ®Google Scholar
• Kaplan, H. R., Taylor, D. G., Olson, S. C. et al. (1989). Quinapril - a preclinical review of the pharmacology, pharmacokinetics and toxicology. Angiology, 40, 335–350.
   PubMed Web of Science ®Google Scholar
• Luft, R C., Miller, J. Z., Grim, C. E. et al. (1991). Salt sensitivity and resistance of blood pressure. Hypertension, 17 (Suppl I), I-102–I-108.
   Google Scholar
• Walker, W. G., Neaton, J. D., Cutler, J. A., Neuwirth, R. and Cohen, J. D. (1992). Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA, 268, 3085–3091.
   PubMed Web of Science ®Google Scholar
• Walker, W. G., Horvath, J. S., Moore, M. A., Whelton, P. and Russell, R. P. (1976). Relation between plasma renin activity, angiotensin, and aldosterone and blood pressure in mild untreated hypertension. Circ. Res., 38, 470–476.
   PubMed Web of Science ®Google Scholar
• Campbell, D. J., Kladis, A., Skinner, S. L. and Whitworth, J. A. (1991). Characterization of angiotensin peptides in plasma of anephric man. J. Hypertens., 9, 265–274.
   PubMed Web of Science ®Google Scholar
• Yamada, T., Horiuchi, M. and Dzau, V. J. (1996). Angiotensin II type 2 receptor mediates programed cell death. Proc. Natl. Acad. Sci. USA, 93(1), 156–160.
   PubMed Web of Science ®Google Scholar
• Kimura, G., Deguchi, F., Kojima, S. et al. (1988). Antihypertensive drugs and sodium restriction. Am. J. Hypertens., 1, 372–379.
   PubMed Web of Science ®Google Scholar
• Joubert, P. H. and Brandt, H. D. (1990). Apparent racial difference in response to angiotensin I infusion. Eur. J. Clin. Phannacol., 39, 183–185.
   PubMed Web of Science ®Google Scholar
• Sharma, A. M, Schattenfroh, S., Thiede, H. M., Oelkers, W. and Distler, A. (1992). Effects of sodium salts on pressor reactivity in salt-sensitive men. Hypertension, 19, 541–548.
   PubMed Web of Science ®Google Scholar
• Redgrave, J., Rabinowe, S., Hollenberg, N. K. and Williams, G. H. (1985). Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertension. J. UM. Invest., 75, 1285–1290.
   PubMed Web of Science ®Google Scholar
• Stokes, J. B. III (1974). The national high blood pressure education program. J. Am. Pharm. Assoc., 14, 172–176.
   PubMedGoogle Scholar
• The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI). Arch. Intern. Med., 157(21), 2413–2446.
   PubMed Web of Science ®Google Scholar
• Dannenberg, A. L., Drizd, T., Horan, M. J. et al. (1987). Progress in the battle against hypertension. Changes in blood pressure levels in the United States from 1960 to 1980. Hypertension, 10, 226.
   PubMed Web of Science ®Google Scholar
• Roberts, J. (1975). Blood pressure of persons 18–74 years: United States, 1971–72. Data from the National Health Survey, Washington, DC; National Center for Health Statistics, 1975. Vital and Health Statistics, Series 11, No. 150. DHEW Publication No. 75–1632.
   Google Scholar
• Rowland, M. and Roberts, J. (1982). Blood pressure levels and hypertension in persons aged 6–74 years: United States, 1976–80. National Center for Health Statistics, Hyattsville, Md; October, 1982. Advance Data from Vital and Health Statistics, No. 84. DHHS Publication No. 82–1250.
   Google Scholar
• Burt, V. L., Whelton, P., Roccella, E. J., et al. (1995). Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 25, 305–313.
   PubMed Web of Science ®Google Scholar
• Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B. and Castelli, W. P. (1990). Prognostic implications of echocardio-graphically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med., 322, 1561–1566.
   PubMed Web of Science ®Google Scholar
• Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D. and Laragh, J. H. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med., 114, 345–352.
   PubMed Web of Science ®Google Scholar
• Cooper, R. S., Simmons, B. E., Castaner, A., Santhanam, V, Ghali, J. and Mar, M. (1990). Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am. J. Cardiol., 65, 441–445.
   PubMed Web of Science ®Google Scholar
• Ghali, J. K., Liao, Y., Simmons, B., Castaner, A., Cao, G. and Cooper, R. S. (1992). The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann. Intern. Med., 117, 831–836.
   PubMed Web of Science ®Google Scholar
• Mensah, G. A, Liao, Y. and Cooper, R. S. (1995). Left ventricular hypertrophy as a risk factor in patients with or without coronary artery disease. Cardiovasc. Risk Factors, 5, 67–74.
   Google Scholar
• Schunkert, H., Jackson, B., Tang, S. S. et al. (1993). Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation, 87, 1328–1339.
   PubMed Web of Science ®Google Scholar
• Kaneko, K., Susic, D., Nunez, E. and Frohlic, E. D. (1997). ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am. J. Med. Sci., 314(1), 21–27.
   PubMed Web of Science ®Google Scholar
• Dahlof, B. and Hannson, L. (1992). Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorthiazide. J. Hypertension, 10, 1513–1524.
   PubMed Web of Science ®Google Scholar
• Papademetriou, V. (1994). Effects of diuretics on cardiac arrhythmias and left ventricular hypertrophy in hypertension. Cardiology, 84 (Suppl 2), 43–47.
   PubMedGoogle Scholar
• Agabiti-Rosei, E., Muiesan, M. L., Rizzoni, D., Zulli, R. et al. (1994). Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J. Cardiovasc. Pharmacol., 24 Suppl A, S37–S43.
   PubMed Web of Science ®Google Scholar
• Szlacheie, J., Tuban, J. F., Vollmer, C. et al. (1989). Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am. J. Cardiol., 63, 198–201.
   PubMed Web of Science ®Google Scholar
• Glasser, S. P., Koehn, D. K. and Powell, R. (1989). Regression of left ventricular hypertrophy in treated hypertensive patients with dievanol and metoprolol – a double blind randomized study. J. Clin. Phannacol., 29, 791–797.
   Web of Science ®Google Scholar
• de Divitis, O., Celentano, A., De Simone, G. et al. (1993). Management of the patient with left ventricular hypertrophy. Eur. Heart J., 14 (Suppl D), 22–32.
   Web of Science ®Google Scholar
• Oliveri, R. (1988). Effects of different antihypertensive drugs on left ventricular function. Drugs, Suppl 35 (Suppl 6), 83–89.
   PubMedGoogle Scholar
• Cruickshank, J. M. (1992). Reversibility of left hypertrophy. Blood Pressure, 1 (Suppl 1), 32–33.
   Google Scholar
• Dahlof, B., Pennert, K. and Hansson, L. (1992). Regression of left ventricular hypertrophy - a meta-analysis. Clin. Expl. Hyp. Part A, 14(1–2), 173–180.
   PubMed Web of Science ®Google Scholar
• Koren, M. J., Mensah, G. A., Blake, J., Laragh, J. H. and Devereux, R. B. (1993). Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am. J. Hypertens., 6, 815–823.
   PubMed Web of Science ®Google Scholar
• Brilla, C. G., Maisch, B. and Weber, K. T. (1993). Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. UM. Invest., 71, S35–S41.
   Google Scholar
• Weber, K. T. (1989). Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol., 13, 1637–1652.
   PubMed Web of Science ®Google Scholar
• Lund-Johansen, P. and Omvik, P. (1993). Cardiac effects of ACE inhibition. J. Cardiovasc. Pharmacol., 22 (Suppl 1), S36–S40.
   PubMedGoogle Scholar
• Federman, M., Risti, B. and Hess, O. M. (1994). Left venticular insuffiency: systolic versus diastolic dysfunction (in German). Schweizerrishe Medizinische Wochensch rift. Journal Suisse de Medecine, 124(26), 1196–1202.
   Google Scholar
• Brilla, C. G., Scheer, C. and Rupp, H. (1997). Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J. Hypertens., 15(6) (Suppl), S13–S19.
   Google Scholar
• Sun, Y. (1997). Local angiotensin II and myocardial fibrosis. Adv. Expl. Med. Biol., 432, 55–61.
   PubMed Web of Science ®Google Scholar
• Funck, R. C., Wilke, A., Rupp, H. and Brilla, C. G. (1997). Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv. Expl. Med. Biol., 432, 35–44.
   PubMed Web of Science ®Google Scholar
• Garg, R, Packer, M., Pitt, B. and Yusuf, S. (1993). Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J. Am. Coll. Cardiol., 22, 3A–5A.
   PubMed Web of Science ®Google Scholar
• Bourassa, M. G., Gurne, O., Bangdiwala, S. I. et al. (1993). Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J. Am. Coll. Cardiol., 22, 14A–19A.
   PubMed Web of Science ®Google Scholar
• Stafford, R. S., Saglam, D. and Blumenthal, D. (1997). National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch. Intern. Med., 157 (21), 2460–2464.
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med., 316, 1429–1435.
   PubMed Web of Science ®Google Scholar
• Struthers, A. D. (1997). Rationalizing the heart failure trials: from theory to practice. Eur. Heart J., 18 (Suppl E), E5–E8.
   PubMed Web of Science ®Google Scholar
• Maynard, C., Fisher, L. D., Passamani, E. R. et al. (1986). Blacks in the coronary artery surgery study: risk factors and coronary artery disease. Circulation, 74, 64.
   PubMed Web of Science ®Google Scholar
• Simmons, B. E., Castaner, A., Campo, A. et al. (1988). Coronary artery disease in blacks of lower socioeconomic status: angiographic findings from the Cook County Hospital Heart Disease Registry. Am. Heart J., 116, 90–97.
   PubMed Web of Science ®Google Scholar
• Strong, J. P., Oalmann, M. C., Newman, W. P. III et al. (1984). Coronary heart disease in young black and white males in New Orleans: Community Pathology Study. Am. Heart J., 108, 747–759.
   PubMed Web of Science ®Google Scholar
• Tofler, G. H., Stone, P. H., Muller, J. E. et al. (1987). Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J. Am. Coll. Cardiol., 9, 473–482.
   PubMed Web of Science ®Google Scholar
• Mensah, G. A., Cooper, R. S. and Liao, Y. (1994). Sex-related outcome differences after acute myocardial Infarction (corr). Ann. Intern. Med., 121, 815–816.
   PubMed Web of Science ®Google Scholar
• Pfeffer, M. A., Braunwald, E., Moye, L. A. et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med., 327, 669–677.
   PubMed Web of Science ®Google Scholar
• Blythe, W. B. and Maddux, F. W. (1991). Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am. J. Kidney Dis., 18, 33–37.
   PubMed Web of Science ®Google Scholar
• Reiman, A. S. (1982). Race and end-stage renal disease [Editorial]. N. Engl. J. Med., 306, 1290–1291.
   PubMed Web of Science ®Google Scholar
• Perneger, T. V., Whelton, P. K., Klag, M. J. and Rossiter, K. A. (1995). Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am. J. Epidemiol., 141, 10–15.
   PubMed Web of Science ®Google Scholar
• Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F L. and Stamler, J. (1997). End-stage renal disease in African-American men: 16-year MRFIT findings. JAMA, 277, 1293–1298.
   PubMed Web of Science ®Google Scholar
• Lewis, E. J., Hunsicker, L. G., Bain, R. P. and Rohde, R. D. for the Collaborative Study Group (1993). The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N. Engl. J. Med., 329, 1456–1462.
   PubMed Web of Science ®Google Scholar
• Giatras, I., Lau, J. and Levey, A. S. for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group (1997). Effect of angiotensin-convertingenzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann. Intern. Med., 127, 337–345.
   PubMed Web of Science ®Google Scholar
• Saunders, E., Weir, M. R., Kong, B. W. et al. (1990). A comparison of the efficacy and safety of a beta-blocker, a calcium blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med., 150, 1707–1713.
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents (1982). Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. Results of short-term titration with emphasis on racial difference in response. JAMA, 248, 1996–2003.
   PubMed Web of Science ®Google Scholar
• Wing, W., Ferguson, R. K. and Vlasses, P. H. (1991). Calcium antagonist in elderly and black hypertensive patients. Arch. Intern. Med., 1551, 2154–2162.
   Google Scholar
• Drayer, J. I. M. and Weber, M. A. (1983). Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension, 5 (Suppl III), III-108–III-113.
   Google Scholar
• Flack, J. M. Personal communication.
   Google Scholar
• Weir, M. R., Hall, P. S., Behrens, M. T. and Flack, J. M. (1997). Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension, 30(3, Pt 1), 422–427.
   PubMed Web of Science ®Google Scholar
• Mikami, H., Suzuki, H., Smeby, R. R. and Ferrario, C. M. (1985). Cerebrospinal fluid angiotensin II immunoreactivity is not derived from the plasma. Hypertension, 7, 65–71.
   PubMed Web of Science ®Google Scholar